13 results about "Dermatan sulfate" patented technology

Biomaterials disclosed herein can comprise a hydrogel comprising PEG, gelatin, and a glycosaminoglycan with sulfated moiety; and chondrogenic, osteogenic, and immunomodulatory cytokines; wherein the biomaterial is capable of potentiating bone regeneration in a compromised wound while reducing inflammatory response. The glycosaminoglycan with sulfated moiety can comprise heparin, heparan sulfate, keratin sulfate, chondroitin sulfate, dermatan sulfate, and / or similar materials. The biomaterial can further comprise mesenchymal stem cells (MSCs), a crosslinking initiator, microparticles and nanoparticles, and or other materials. The biomaterial can be injectable into a wound, or the biomaterial can be loaded in, or further comprise a porous scaffold providing mechanical support for other components of the biomaterial, such that it can be implanted into a wound.

The invention provides chondroitin sulfate excision enzyme and application of the chondroitin sulfate excision enzyme in dermatan sulfate preparation. The amino acid sequence of the chondroitin sulfate excision enzyme is shown as SEQ ID NO: 3, and the chondroitin sulfate excision enzyme has broad-spectrum substrate specificity and can efficiently degrade hyaluronic acid and glycosaminoglycans such as chondroitin sulfate (A, C, E and D). The chondroitin sulfate excision enzyme can efficiently act on a substrate by virtue of a unique catalytic mechanism, so that efficient preparation of oligosaccharide and low-molecular-weight polysaccharide is realized, and the chondroitin sulfate excision enzyme can be particularly used for enzymatic preparation of dermatan sulfate. The chondroitin sulfate excision enzyme has efficient catalytic performance and unique treatment advantages, not only fills the technical blank in related fields, but also opens up a wide space for the development of carbohydrate chemicals in the fields of biological medicines, cosmetics, foods and the like.

Biomaterials disclosed herein can comprise a hydrogel comprising PEG, gelatin, and a glycosaminoglycan with sulfated moiety; and chondrogenic, osteogenic, and immunomodulatory cytokines; wherein the biomaterial is capable of potentiating bone regeneration in a compromised wound while reducing inflammatory response. The glycosaminoglycan with sulfated moiety can comprise heparin, heparan sulfate, keratin sulfate, chondroitin sulfate, dermatan sulfate, and / or similar materials. The biomaterial can further comprise mesenchymal stem cells (MSCs), a crosslinking initiator, microparticles and nanoparticles, and / or other materials. The biomaterial can be injectable into a wound, or the biomaterial can be loaded in, or further comprise a porous scaffold providing mechanical support for other components of the biomaterial, such that it can be implanted into a wound.

The invention provides a composition capable of tightening vagina and recovering elasticity and a preparation method thereof, and the composition comprises the following components in parts by mass: 75-130 parts of a collagen structure repairing unit, 25-55 parts of a composite cross-linking agent, 8-35 parts of a fibroblast activating factor and 12-38 parts of a plant tannin delivery body. The problem of membrane permeation is solved through high-activity hydrolyzed collagen peptide, a difunctional cross-linking system is formed by chemical grafting of dermatan sulfate and carboxymethyl beta-glucan, the fibroblast activation efficiency is enhanced by means of a zinc ion mediated polypeptide complexing structure, and the bottleneck in the prior art is remarkably broken through on key indexes.

Provided herein are selectin-binding peptide ligands having both D- and L-amino acids, and peptide conjugates including the provided peptide ligands. The peptide conjugates can include a biopolymer backbone, such as dermatan sulfate, and 33 or fewer peptide ligands conjugated to the biopolymer. Also provided are methods for using the provided peptide conjugates to treat patients suffering from endothelial dysfunction.

The invention belongs to the technical field of dermatan sulfate application, and particularly relates to application of dermatan sulfate in promotion of cholesterol excretion. The cholesterol excretion promoting effect of dermatan sulfate is discussed through in-vivo and in-vitro experiments, and results show that dermatan sulfate has the effect of promoting cholesterol excretion of liver cells, not only can reduce blood fat and liver lipid and promote excretion of cholesterol to excrement, but also can inhibit expression of ASGR1, further up-regulates LXR alpha, and has the effect of promoting cholesterol excretion of liver cells. The expression of ABCA1 and ABCG5 transporters is improved to promote cholesterol excretion and reduce the in-vivo lipid level. Therefore, dermatan sulfate is a potential medicine for promoting cholesterol excretion, a new thought is provided for development of a targeted ASGR1 medicine for promoting cholesterol excretion, and a theoretical basis is provided for treatment of cardiovascular diseases such as hypercholesterolemia and the like.

The present application relates to a PL35 family chondroitin sulfate lyase CHa3, a coding gene and application thereof, and belongs to the technical field of enzyme engineering. The chondroitin sulfate lyase CHa3 has an amino acid sequence shown as SEQ ID NO. 2, is a novel chondroitin sulfate lyase, has high enzyme activity on chondroitin sulfate, and degrades chondroitin sulfate into an endo-enzyme mode; when degrading chondroitin sulfate polysaccharide, the end product is a series of unsaturated oligosaccharides, including but not limited to unsaturated disaccharides to unsaturated dodecasaccharides; when degrading heparin, the end product is mainly unsaturated disaccharides; and when degrading dermatan sulfate, the end product includes unsaturated tetrasaccharides to unsaturated octasaccharides. The chondroitin sulfate lyase CHa3 can be applied to the preparation of CS / DS oligosaccharides and the research on the structure and function of CS / DS, and has a wide application prospect in the fields of medicine, food and the like.

The present application relates to a specific hyaluronate lyase and its coding gene and application, and belongs to the technical field of biology and enzyme engineering. The specific hyaluronate lyase sHAase is an amino acid sequence as shown in SEQ ID NO. 1, or an amino acid sequence with homology of > 90% to the amino acid sequence shown in SEQ ID NO. 1, or an amino acid sequence formed by modifying, substituting, deleting or adding at least one amino acid in the amino acid sequence shown in SEQ ID NO. 1, and still having hyaluronic acid degradation activity. The present application also provides the coding gene, preparation method and use of the specific hyaluronate lyase sHAase. The hyaluronate lyase has very high substrate selectivity for hyaluronic acid, does not act on other glycosaminoglycans such as chondroitin sulfate, dermatan sulfate, heparin or heparan sulfate, and can cleave hyaluronic acid into degradation products mainly composed of unsaturated disaccharides, which is conducive to detection and separation.

This invention discloses a collagen conjugate, its preparation method, and its application, belonging to the field of cosmetic technology. The collagen conjugate is obtained by conjugating human recombinant collagen with glycosaminoglycans; the human recombinant collagen includes at least one of human recombinant type I, III, IV, V, VII, and XVII collagen; the glycosaminoglycans include at least one of hyaluronic acid and its sodium salt, chondroitin sulfate and its sodium salt, and dermatan sulfate and its sodium salt. This collagen conjugate not only forms a protective film on the skin surface, providing immediate repair and firming effects and reducing damage to the skin from external stimuli; it also decomposes to produce beneficial substances, promoting the growth of probiotics on the skin surface and maintaining the skin's microecological balance; furthermore, after degradation, the collagen conjugate promotes collagen production, enhancing its effectiveness in improving or preventing wrinkles. This collagen conjugate can be used in the preparation of cosmetics.

The application discloses a fish swim bladder chondroitin sulfate-Dermatan sulfate hybrid chain and a preparation method and application thereof, and relates to the technical field of medicines. The fish swim bladder chondroitin sulfate (CS) / dermatan sulfate (DS) hybrid chain with anticoagulant activity is composed of iduronic acid, N-acetylgalactosamine, glucuronic acid and N-acetylglucosamine, and the CS / DS hybrid chain is derived from a fish swim bladder, is easily soluble in water, has strong anticoagulant activity, and can be used for preparing medicines for preventing and / or treating thrombotic cardiovascular diseases.

The invention belongs to the technical field of biomedical materials, and discloses a bone-imitating organic matrix composite fiber material for bone defect repair as well as a preparation method and application of the bone-imitating organic matrix composite fiber material. The bone-imitating organic matrix composite fiber material is a composite fiber membrane composed of core-shell structure composite fiber filaments prepared through coaxial electrostatic spinning. The core of the core-shell structure composite cellosilk is obtained by compounding polycaprolactone, mesoporous bioactive glass and multi-component glycosaminoglycan, and the shell of the core-shell structure composite cellosilk is obtained by compounding polycaprolactone, silk fibroin and nerve growth factors; the multi-component glycosaminoglycan is prepared from the following components in parts by mass: 6 to 27 parts of hyaluronic acid, 28 to 39 parts of chondroitin sulfate, 4 to 24 parts of dermatan sulfate, 1 to 29 parts of heparin, 14 to 42 parts of heparan sulfate and 0.16 to 0.41 part of keratin sulfate. The bone-imitating organic matrix composite fiber material has a good application prospect in preparation of medicines or medical instruments for promoting bone defect repair.

Applicants sought to express human iduronate-2-sulfatase (hIDS) in the brain endothelium of a mouse model of Mucopolysaccharidosis type II (MPSII, Hunter's syndrome) to enable enzyme secretion into the brain parenchyma. In this disorder, IDS deficiency results in the pathophysiological accumulation of heparan and dermatan sulfate GAGs. To test the hypothesis, Applicants chose AAV-BI30, an AAV9-derived capsid that has an enhanced in vivo tropism specific to the endothelium in the rodent CNS and can transduce human brain vascular endothelial cells in vitro more efficiently than AAV9. Applicants show that systemic delivery of AAV-BI30: hIDS restored IDS enzyme activity in the brain, liver, and serum of IDS-KO mice (FIG. 1). Importantly, AAV-BI30-mediated gene transfer resulted in the correction of GAG accumulation in the brain (FIG. 2). This effect was not observed when using the AAV-BI30 vector packaging a non-secreting version of hIDS. These findings highlight that targeting endothelial cells throughout the CNS is a promising approach for delivering enzymes across the BBB and restoring lysosomal metabolism.

The invention relates to the field of new daily chemical materials, in particular to a cyclic antioxidant composition which comprises the following components in parts by weight: 0.01-0.1 part of total molecular weight sodium hyaluronate; 0.01 to 1 part of cerium oxide; 0.0001 to 0.002 part of sodium dermatan sulfate; the composition has high initial oxidation resistance, has good continuous oxidation resistance in the long-term use process, can maintain the characteristics under the illumination condition, and has more obvious advantages compared with traditional oxidation resistance products. Meanwhile, the invention further discloses application and cosmetics of the composition.